亚洲AV片不卡无码久久蜜芽_国产精品免费久久久久影院_国产精品一区二区久久不卡_精品国产污污免费网站

語言選擇:簡體 / 繁體 / English

羅欣藥業 傳遞健康

山東羅欣藥業(ye)集團股份有限公司招標公告

羅欣藥業 傳遞健康

羅欣藥業 傳遞健康

企業資訊

羅欣藥業與韓國HK inno.N Corporation就引進替戈拉生注射劑產品達成協議

發布時間:2021年06月25日(ri) 瀏覽次數:
分享:

11.jpg

中國上海,2021年6月(yue)24日 - 羅(luo)欣(xin)(xin)藥(yao)業集(ji)團股(gu)份有(you)限(xian)公司(si)(si)(以下簡稱(cheng)“羅(luo)欣(xin)(xin)藥(yao)業”)子公司(si)(si)山東(dong)羅(luo)欣(xin)(xin)藥(yao)業集(ji)團股(gu)份有(you)限(xian)公司(si)(si)(以下簡稱(cheng)“山東(dong)羅(luo)欣(xin)(xin)”)宣布與(yu)韓國HK inno.N Corporation(原CJ HealthCare Corporation公司(si)(si),以下簡稱(cheng)“HK inno.N Corporation”)在線簽署合作(zuo)協議,就引進HK inno.N Corporation公司的替戈拉生注射劑產品達成合作。山東羅欣將獲得該產品在中國的獨家開發、生產和商業化權利。目(mu)前(qian),替戈拉生注射劑在(zai)全球范(fan)圍內尚(shang)無產品上市。

Shanghai,China, June 24, 2021-- Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.(Shandong Luoxin), a subsidiary of Luoxin Pharmaceutical Group Stock Co., Ltd. (Luoxin Pharmaceutical) signed a cooperation agreement with South Korea-based HK inno.N Corporation (formerly CJ HealthCare Corporation) whereby Shandong Luoxin will gain the exclusive rights for the development, manufacture, and commercialization of Tegoprazan injections in China. At present, Tegoprazan injections are not yet available anywhere worldwide. The signing event took place online.

22.jpg

33.jpg

圖為簽約儀(yi)式現(xian)場  

替(ti)戈拉(la)生(sheng)是(shi)鉀離子競爭性(xing)酸(suan)阻滯劑類藥物(wu)(Potassium-Competitive Acid Blockers,P-CAB),其抑(yi)制(zhi)(zhi)酸(suan)分(fen)泌的作用(yong)機制(zhi)(zhi)為競爭性(xing)結(jie)合壁細胞(bao)內(nei)H+/K+-ATP酶(mei)(質子泵)的鉀離子結(jie)合部位。與(yu)傳統(tong)質子泵抑(yi)制(zhi)(zhi)劑(PPI)不(bu)同(tong),P-CAB可直接抑(yi)制(zhi)(zhi)H+/K+-ATP酶(mei),而(er)(er)無需在強酸(suan)環境下(xia)活(huo)化。而(er)(er)且,無論(lun)H+/K+-ATP酶(mei)活(huo)化與(yu)否,P-CAB均可與(yu)之結(jie)合。替(ti)戈拉(la)生(sheng)注射(she)劑主要用(yong)于治療胃食管反(fan)流、上消(xiao)化道出血(xue)和預防應激(ji)性(xing)胃黏膜損傷等(deng),具有(you)起(qi)效快、作用(yong)時(shi)間(jian)長(chang)、酸(suan)性(xing)條件(jian)下(xia)穩(wen)定、可同(tong)時(shi)抑(yi)制(zhi)(zhi)激(ji)活(huo)和靜息狀態質子泵等(deng)特點。 

Tegoprazan, a novel potassium-competitive acid blocker (P-CAB), inhibits gastric H+/K+-ATPase (proton pump) in a potassium-competitive and reversible manner.Different from the traditional proton pump inhibitors (PPI), P-CAB can directly inhibit H+/K+-ATPase without activation in strong acid environments. Moreover, P-CAB can be combined with H+/K+-ATPase whether it is activated or not. Tegoprazan injections have mainly been developed for the treatment of acid-related gastrointestinal diseases such as gastroesophageal reflux disease (GERD) and upper gastrointestinal bleeding as well as for the prevention of stress gastric mucosa injury. The drug has many advantages, including fast onset of action, effectiveness over a prolonged period and stability under acidic conditions that can simultaneously inhibit both activated and resting state proton pumps.

根(gen)(gen)據IQVIA數據,2020年中(zhong)(zhong)(zhong)國質子(zi)泵(beng)抑制(zhi)劑(PPI)藥物市(shi)場(chang)規(gui)模(mo)約(yue)(yue)30億美(mei)(mei)元(yuan),僅(jin)次于美(mei)(mei)國位居全(quan)球第二,其中(zhong)(zhong)(zhong)注(zhu)射劑市(shi)場(chang)規(gui)模(mo)約(yue)(yue)20億美(mei)(mei)元(yuan),約(yue)(yue)128億人(ren)民(min)幣,占PPI藥物市(shi)場(chang)的60%。根(gen)(gen)據協議(yi)條款(kuan),山(shan)東羅欣(xin)將(jiang)獲得替戈拉(la)生注(zhu)射劑產(chan)(chan)品在中(zhong)(zhong)(zhong)國的獨家開發(fa)、生產(chan)(chan)和商業化權益,并將(jiang)向HK inno.N Corporation支付(fu)總計不(bu)超(chao)過500萬美(mei)(mei)元(yuan)的首付(fu)款(kuan)及(ji)銷售里程(cheng)碑付(fu)款(kuan)。

Statistics from IQVIA reveal that China’s PPI market amounted to about US$3 billion in 2020, ranking second in the world just behind the U.S. The market for injections reached nearly 2 billion (approx.12.8 billion yuan), accounting for 60 percent of the total PPI drug market.Under the agreement, Shandong Luoxin will receive the exclusive development, manufacture, and commercial rights of Tegoprazan injections in China, and pay up to US$5 million in total down payments and sales milestone payments.

HK inno.N Corporation代表(biao)理事姜碩禧(Kang Seok-hee)表(biao)示:“羅欣藥業(ye)作為我們鉀離子競爭性酸(suan)阻滯劑類藥物在中(zhong)國的(de)開發合作伙伴,具有消化領域(yu)強大競爭能力以(yi)及(ji)出色(se)的(de)商業(ye)能力。我很高興(xing)雙方可以(yi)達成進一步合作,增加Tegoprazan產品在中(zhong)國市場價(jia)值(zhi)。”

HK inno.N Corporation CEO Kang Seok-hee said “As the development partner of our P-CAB in China, Luoxin Pharmaceutical has strong competitive and excellent business capabilities in the digestion sector. I am pleased that the two sides have been able to enter into this cooperation with the aim of increasing the value of Tegoprazan in the Chinese market.”

“我們與HK inno.N Corporation公司一直保持良好的合作伙伴關系(xi),愿雙(shuang)方共同探索創新(xin)藥物的努力(li)早(zao)日(ri)取得(de)成果,為全(quan)球病患提供更有價值的創新(xin)療法(fa),也期待在未來(lai)拓展更多合作空(kong)間。”羅欣藥業董事(shi)長兼(jian)CEO劉振騰(teng)表示(shi)。

Luoxin Pharmaceutical chairman and CEO Ryan Liu noted “We have maintained a good partnership with HK inno.N Corporation and hope the joint efforts to explore innovative drugs can pay off as soon as possible and provide more effective therapies to patients worldwide. We are looking forward to further expansion of the cooperation in the future.”

羅欣藥業與HK inno.N Corporation(原CJ HealthCare Corporation)合作始于2015年(nian)(nian),雙方就替戈拉生(sheng)片在(zai)中國境(jing)內獨家開發、生(sheng)產及商業化(hua)權(quan)益達成協議。2017 年(nian)(nian) 6 月該項目(mu)獲(huo)得(de)臨(lin)床(chuang)試驗(yan)批件(jian),2019年(nian)(nian)首個III期臨(lin)床(chuang)研究結(jie)果達到主要療效(xiao)終(zhong)點。目(mu)前(qian),替戈拉生(sheng)片上市申請已獲(huo)CDE受理。

The collaboration between Luoxin Pharmaceutical and HK inno.N Corporation (formerly CJ HealthCare Corporation) began in 2015, when they reached an agreement on the exclusive development, production and commercial rights of Tegoprazan in China. Clinical trial approval was obtained in June 2017, while the first phase III clinical study results reached the main efficacy end point in 2019. At present, the marketing authorization application for Tegoprazan has been accepted by China's Center for Drug Evaluation (CDE).


*** 

【關于韓國HK inno.N Corporation】

HK inno.N Corporation公(gong)司(si)是一家即將在韓(han)(han)國(guo)(guo)交(jiao)易(yi)所上市(shi)的(de)集團公(gong)司(si),已向韓(han)(han)國(guo)(guo)交(jiao)易(yi)所遞交(jiao)上市(shi)申請。自1984年成立以來,憑(ping)借(jie)其(qi)處(chu)方(fang)藥(yao)(yao),如腸(chang)胃藥(yao)(yao)、抗(kang)癌藥(yao)(yao)、循環系統藥(yao)(yao)、糖(tang)尿(niao)病藥(yao)(yao)及(ji)腎藥(yao)(yao),及(ji)非處(chu)方(fang)藥(yao)(yao)品組合,于韓(han)(han)國(guo)(guo)藥(yao)(yao)品市(shi)場獨(du)占(zhan)鰲頭(tou)。公(gong)司(si)于2018年2月18日被韓(han)(han)國(guo)(guo)Kolmar Korea Co.,Ltd收購,并于2020年2月6日完(wan)成官方(fang)注冊名稱變更,從原CJ HealthCare Corporation正式(shi)更名為HK inno.N Corporation。

HK inno.N Corporation is a biotechnology and pharmaceutical company that is the process of applying to launch an IPO on the Korea Stock Exchange. Since inception in 1984, the firm has dominated the South Korean drug market with its lineup of prescription drugs for the treatment of gastrointestinal, kidney and circulatory aliments as well as cancer and diabetes, alongside an over-the-counter drug portfolio. The company was acquired by Kolmar Korea Co., Ltd on February 18, 2018, and completed its official registration for a name change on February 6, 2020, from the original CJ HealthCare Corporation to HK inno.N Corporation. 

 

【關于(yu)羅欣藥業】

羅欣藥(yao)(yao)業(ye)集(ji)團股份有限公司(si)(以下簡稱(cheng)“羅欣藥(yao)(yao)業(ye)”)是(shi)集(ji)藥(yao)(yao)品研發、生產、貿易及醫(yi)(yi)療(liao)健(jian)康服務為一體的大型(xing)醫(yi)(yi)藥(yao)(yao)企業(ye)集(ji)團。躋身發展速度(du)領(ling)先的中國制藥(yao)(yao)企業(ye)方陣,羅欣藥(yao)(yao)業(ye)致力于為客戶提供(gong)高品質原料藥(yao)(yao)、多(duo)劑(ji)型(xing)藥(yao)(yao)物(片劑(ji)、膠囊劑(ji)、注射劑(ji)等)和醫(yi)(yi)療(liao)健(jian)康服務。

羅欣藥業(ye)連續多(duo)(duo)年位(wei)列中(zhong)國制藥工業(ye)百強企(qi)(qi)業(ye)榜(bang)單,且(qie)多(duo)(duo)次(ci)被評為“制藥企(qi)(qi)業(ye)研(yan)發實力20強”,已于2019年登陸(lu)中(zhong)國A股市場,股票代(dai)碼002793。

Luoxin Pharmaceutical Group (Luoxin Pharmaceutical) is a healthcare conglomerate that is engaged in health services as well as the R&D, manufacture and sales of pharmaceuticals. As one of the fastest-growing and leading pharmaceutical companies in China, Luoxin Pharmaceutical is committed to providing customers with high-quality API, multi-agent drugs (tablets, capsules and injections) and healthcare services.

Luoxi Pharmaceutical has been included in the list of China’s top 100 pharmaceutical producers for several consecutive years and been named among the Top 20 Pharmaceutical Companies By R&D Strength multiple times. Its shares were listed on China’s A-share market in 2019, with the stock code 002793.